Access widened to funded medicines

Last updated 05:00 13/11/2012

Relevant offers

Politics

High turnover of staff in National MP's office and claims of bullying Crown Law solicitors paid more to prosecute dog owners than murderers Stacey Kirk: Moko's killers deserve life in jail - they've already gotten away with murder Does Brexit wreck it for New Zealand? Trade Minister to meet with EU and UK to discuss impact of Brexit on Kiwi exporters Jonathan Milne: Sorry Boris, you can't come crawling back to the Commonwealth, the days of Empire are gone Moko: Hit, kicked, thrown, bitten, stomped and smothered – but prosecutors can't prove couple murdered the boy NZ cigarette plain packaging law would see Imperial Tobacco sue for compensation Guy Williams: How to take down the National Party Powerful NZ dame: UK ties to become deeper, stronger and more significant

Pharmac has spent more than $21.5 million on new drugs and widening access to publicly funded medicines in the past year.

Blood thinning drug Pradaxa, also known as dabigatran, was the most expensive new drug to be funded, with an estimated annual cost of $16 million.

Two new drugs targeting specific types of breast and kidney cancer were also added to the list of funded medications.

More people can access the drug rituximab, which is used to treat some kinds of lymphomas. Breast cancer drug docetaxel has also been made more widely available and access to funded treatment for Crohn's disease, Cystic fibrosis and asthma were widened.

The Government's drug-buying agency yesterday released its annual report for the year ending June 30, which showed 14 new medicines were funded in the past year and access to 10 others was widened.

An extra 56,840 patients were expected to benefit from the changes, on top of the record 3.3 million New Zealanders who received fully funded medication in the past year.

Pharmac stayed within its $777.4m budget in a year which saw it take on additional roles, including managing the national immunisation schedule and hospital medicines and medical devices.

It also contributed $379,000 towards a research trial in Finland looking at whether the nine week or 12-month duration of breast cancer drug Herceptin offers a better treatment.

Ad Feedback

- The Dominion Post

Special offers
Opinion poll

Where do you stand on political coat-tail riding?

If it gets marginalised voices into Parliament, I'm for it.

I'm against it - if you don't get the votes, you shouldn't be there.

It's just part of the political game.

Vote Result

Related story: Voters reject riding on the coat-tails

Featured Promotions

Sponsored Content